Eli Lilly's Oral Weight-Loss Drug Foundayo Launches in the UK
Nashnova编辑部
Eli Lilly's new oral weight-loss pill Foundayo (orforglipron) has received MHRA approval and launched in the UK — available only through private prescriptions for now, marking the first commercial landing of an oral GLP-1 drug in the country.
What is this drug, and why does it matter?
Foundayo's generic name is orforglipron, a GLP-1 receptor agonist — a class of drugs that mimic the body's fullness signals, reducing appetite.
The key difference: today's blockbuster weight-loss drugs (e.g. semaglutide) require injections. Foundayo is an oral tablet.
This means → if efficacy holds up, patients who avoid needles gain a real option, and the pill form is far easier to scale.
What exactly did the UK regulator approve?
The MHRA granted marketing authorisation on August 10.
This marks Foundayo's first commercial step globally — moving from regulatory clearance to a product patients can actually obtain.
In plain terms = the drug now has its licence to sell in the UK.
Can ordinary patients access it now?
Initially, Foundayo is limited to private prescriptions — it is not yet covered by the NHS (the UK's publicly funded healthcare system).
This means → only patients willing to pay out of pocket can use it in the short term; the addressable audience is narrow.
For Lilly, the strategic point is different: establishing a commercial foothold for oral GLP-1 in the UK market, laying the groundwork for eventual NHS inclusion.
Content is for reference only, not financial advice.